Key facts
- It has raised $91.5M across 3 recorded rounds; the latest was Early Stage VC ($27.4M) in Jul 2024.
- Notable investors include Alumni Ventures, US National Science Foundation, Harvard Innovation Launch Lab, The Engine, Innovation Endeavors — 19 tracked in total.
- GRO Biosciences has filed 4 Form Ds with the SEC since 2017, most recently Jul 2024 ($27.4M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for GRO Biosciences
Funding rounds
3 roundsAbout GRO Biosciences
Developer of a protein therapeutics technology designed to develop improved treatments across multiple disease classes, including diabetes, growth disorders, and autoimmunity. The company's technology utilizes computational protein design and synthetic biology and has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins, providing medical professionals with proteins that have increased potency, stability, and targeted delivery.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2016
- Employees
- 35
- Website
- grobio.com/
- Ownership
- Privately Held (backing)
GRO Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GRO Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GRO Biosciences in its N-PORT filings yet. We sweep new filings monthly.